Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

m = 1, 2, 3, or 4;

n = 0, 1, 2, 3, or 4;

X is a bond, O, NH or $S(O)_k$, wherein k is 0, 1 or 2;

A is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H_2$, $-SO_3H$, $-PO(R^8)OH$,



each R^1 is independently selected from the group consisting of: hydrogen, halo, hydroxy, $-CO_2H$, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkylthio and aryl, wherein said C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylthio are each optionally substituted from one up to the maximum number of substitutable positions with halo and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C_{1-4}alkyl, or

when m is 2, 3, or 4, two R^1 groups on adjacent carbon atoms may be joined together to form a double bond;

each R^3 is independently selected from the group consisting of: hydrogen, halo, hydroxy, $-CO_2H$, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkylthio and aryl, wherein said C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylthio are each optionally substituted from one up to the maximum number of substitutable positions with halo and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C_{1-4}alkyl, or

when n is 2, 3, or 4, two R^3 groups on adjacent carbon atoms may be joined together to form a double bond;

R^2 and R^4 are each independently selected from the group consisting of: hydrogen, halo, hydroxy, $-CO_2H$, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkylthio and aryl, wherein said C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylthio are each optionally substituted from one up to the maximum number of substitutable positions with halo and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C_{1-4}alkyl;

or R^1 and R^2 or R^3 and R^4 residing on the same carbon atom may optionally be joined together to form a carbonyl group,

each R^5 is independently selected from the group consisting of: halo, aryl, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkylthio and C_{3-6}cycloalkoxy, said C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkylthio and C_{3-6}cycloalkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

R^8 is selected from the group consisting of: C_{1-4}alkyl and aryl, wherein said C_{1-4}alkyl is optionally substituted with 1-3 halo groups and aryl is optionally substituted with 1-5 substituents independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-4}alkylthio and C_{3-6}cycloalkoxy, said C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-4}alkylthio and C_{3-6}cycloalkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

C is selected from the group consisting of:

(1) C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl optionally substituted with phenyl, and

(2) phenyl or HET, each optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of: halo, phenyl, C_{1-4}alkyl, C_{1-4}alkoxy and aralkyl, said C_{1-4}alkyl and C_{1-4}alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl and the aryl portion of aralkyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo, C_{1-4}alkyl and C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy optionally substituted with 1-3 halo groups,

or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: phenyl, C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, -CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl, C_{4-15}alkoxy, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl,

when **C** is phenyl or HET then **B** is selected from the group consisting of: C_{1-6}alkyl, C_{1-5}alkoxy, -(C=O)-C_{1-5}alkyl, -(C=O)-O-C_{1-4}alkyl, -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl, -(C=O)-, -(CHOH)-, phenyl and HET, said phenyl and HET each optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of: halo, phenyl, C_{1-4}alkyl, C_{1-4}alkoxy and aralkyl, said C_{1-4}alkyl and C_{1-4}alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl and the aryl portion of aralkyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo, C_{1-4}alkyl and C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy optionally substituted with 1-3 halo groups, and

when **C** is C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl then **B** is phenyl or HET, said phenyl and HET each optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of: halo, phenyl, C_{1-4}alkyl, C_{1-4}alkoxy and aralkyl, said C_{1-4}alkyl and C_{1-4}alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl and the aryl portion of aralkyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo, C_{1-4}alkyl and C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy optionally substituted with 1-3 halo groups; and

R^6 and R^7 are independently selected from the group consisting of: hydrogen, C_{1-9}alkyl and -$(CH_2)_q$-phenyl, wherein q is 1 to 5 and phenyl is optionally substituted with 1-5 substituents independently selected from the group consisting of: C_{1-3}alkyl and C_{1-3}alkoxy, each optionally substituted with 1-3 halo groups.

2. (original) The compound according to Claim 1 wherein:

Ar is phenyl and

the group **–B-C** is attached to the phenyl ring at the 3- or 4-position.

3. (original) The compound according to Claim 1 wherein X is a bond, m is 2 and n is 2.

4. (original) The compound according to Claim 1 wherein X is selected from O, NH or S, m is 1 and n is 2.

5. (original) The compound according to Claim 1 wherein HET is selected from the group consisting of:



6. (currently amended) The ~~method~~ compound according to Claim 1 wherein **C** is not present and **B** is selected from the group consisting of: C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, -CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl, C_{4-15}alkoxy, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl.

7. (original) The compound according to Claim 1 wherein **C** is phenyl and **B** is selected from the group consisting of: C_{1-6}alkyl, C_{1-5}alkoxy, -(C=O)-C_{1-5}alkyl, -(C=O)-O-C_{1-4}alkyl and -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl.

8. (currently amended) The compound ~~accordin~~ according to Claim 1 wherein:

B-C is selected from the group consisting of:

(1) **B** is C_{7-10}alkyl and **C** is not present,
(2) **B** is C_{6-9}alkoxy and **C** is not present,
(3) **B** is C_{1-6}alkyl or C_{1-5}alkoxy and **C** is phenyl, or
(4) **B-C** is



or



9. (currently amended) ~~A~~ The compound in accordance with Claim 1 wherein:

when X is a bond then m is 2 and n is 2,

when X is O, NH or S then m is 1 and n is 2,

Ar is phenyl and

the group **–B-C** is attached to the phenyl ring at the 3- or 4-position.

10. (original) The compound in accordance with Claim 9 wherein **C** is not present and **B** is selected from the group consisting of: C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, -CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl, C_{4-15}alkoxy, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl.

11. (original) The compound in accordance with Claim 10 wherein **C** is not present and **B** is C_{7-10}alkyl.

12. (original) The compound in accordance with Claim 10 wherein **C** is not present and **B** is C_{6-9}alkoxy.

13. (original) The compound in accordance with Claim 9 wherein **C** is phenyl and **B** is C_{3-6}alkyl.

14. (original) The compound in accordance with Claim 9 wherein **A** is selected from the group consisting of: –CO_2H, -PO_3H_2, -PO_2H_2, -SO_3H and -PO(R^8)OH.

15. (currently amended) A compound selected from the group consisting of:













or a pharmaceutically acceptable salt of any of the above.

16. (original) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

17. (original) The method according to Claim 16 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.

18. (canceled)

19. (original) The method according to Claim 16 wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-

shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.

20 to 27. (canceled)

28. (original) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

29. (original) A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.